maropitant
Sign in to saveMaropitant , sold under the brand name Cerenia among others, when used as maropitant citrate (USAN), is a neurokinin-1 (NK1) receptor antagonist developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs. It was approved by the FDA in 2007, for use in dogs and in 2012, for cats.
Key facts
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.image
- Maropitant.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 175
- Drug.USAN
- maropitant citrate
- Drug.tradename
- Cerenia, others
- Drug.DailyMedID
- Maropitant
- Drug.routes_of_administration
- Oral, subcutaneous, Intravenous transdermal
- Drug.class
- Antiemetic
- Drug.ATCvet
- yes
- Drug.ATC_prefix
- A04
- Drug.ATC_suffix
- AD90
- Drug.legal_CA
- Rx-only
- Drug.bioavailability
- Oral: 20–30% dogs, 50% cats SQ: 90% (both)
- Drug.protein_bound
- 99.5%
- Drug.metabolism
- Liver (CYP3A12 and CYP2D15)
- Drug.metabolites
- CJ-18,518
via Wikipedia infobox
Article
12 sectionsContents
- Veterinary uses
- Contraindications
- Side effects
- Overdose
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- Society and culture
- Legal status
- Names
- References
- External links
Maropitant , sold under the brand name Cerenia among others, when used as maropitant citrate (USAN), is a neurokinin-1 (NK1) receptor antagonist developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs. It was approved by the FDA in 2007, for use in dogs and in 2012, for cats.
Maropitant mildly reduces intra-procedural inhaled anesthesia dose requirements but does not confer analgesia itself.